What Is an Abbreviated New Drug Application (ANDA)
An Abbreviated New Drug Application (ANDA) is a written request to the U.S. Food and Drug Administration (FDA) to manufacture and market a generic drug in the United States. Abbreviated New Drug Applications are “abbreviated” since they do not require the applicant to conduct clinical trials and require less information than a New Drug Application.
- An ANDA is a request to the U.S. Food and Drug Administration (FDA) to manufacture and market a generic drug in the United States.
- The ANDA does not require the applicant to conduct clinical trials.
- An ANDA-approved drug must be bioequivalent to the brand-name drug.
- If an ANDA is approved, it is listed in the Orange Book as an FDA-approved medicine.
Abbreviated New Drug Applications (ANDA) Explained
A company that intends to market a generic drug needs to show the FDA that the drug has been found to be bioequivalent, which means that it can reach the part of the body where the drug works at the same time and in the same amount as the brand-name drug. This qualification is achieved by testing the generic version of the drug against the brand-name version on a small group of test subjects.
The statistical analysis of the test samples must show that there is no significant difference between the generic drug and the brand-name drug. This analysis process is considerably less rigorous than the clinical trials that new drugs must go through. An exception applies to biosimilars, the generic equivalents of biologic drugs. Biosimilars may require clinical trials because it is harder to achieve bioequivalence with these drugs.
The FDA publishes all ANDAs or generic drug approvals each year. See the first-time generic drug approvals for 2018.
An ANDA lists the new drug’s established name, trade name (if any), chemical name, dosage form(s), and strength(s), route of administration, and proposed use. The ANDA asks for the name of the listed drug product to which the proposed generic is an equivalent. The ANDA also addresses whether the drug is for the treatment of a rare disease and whether the drug will be over-the-counter or prescription-only. The applicant may be required to attach supplemental data on drug chemistry, manufacturing and controls, and other technical information.
If an ANDA is approved, the generic drug will be listed in the Orange Book, which lists all medicines the FDA has found to be safe, effective, and low-cost alternatives for the public. An ANDA contains the information the FDA needs to evaluate how safe and effective a proposed generic drug is compared with its brand-name equivalent. The FDA will not approve the generic unless it is equally safe and effective.
The filing of an ANDA does not guarantee approval of the drug by the FDA; interested investors should examine the 10-K report submitted by the company.
Generic drugmakers will typically file an ANDA when the patent protection period of a brand-name drug is about to expire. As a result, news of an ANDA filing can cause the share price of a brand-name drugmaker to drop and the share price of a generic drugmaker to climb, creating a new revenue opportunity for the latter. Investors should note that filing an ANDA does not guarantee approval by the FDA, and so they should do their due diligence when an ANDA is filed by examining the submitted 10-K report of the drugmaker.